The present disclosure relates to heart valve replacement and, in particular, to collapsible prosthetic heart valves. More particularly, the present disclosure relates to collapsible prosthetic heart valves for use in the mitral valve annulus.
Prosthetic heart valves that are collapsible to a relatively small circumferential size can be delivered into a patient less invasively than valves that are not collapsible. For example, a collapsible valve may be delivered into a patient via a tube-like delivery apparatus such as a catheter, a trocar, a laparoscopic instrument, or the like. This collapsibility can avoid the need for a more invasive procedure such as full open-chest, open-heart surgery.
Collapsible prosthetic heart valves typically take the form of a valve structure mounted on a stent. There are two types of stents on which the valve structures are ordinarily mounted: a self-expanding stent and a balloon-expandable stent. To place such valves into a delivery apparatus and ultimately into a patient, the valve is generally first collapsed or crimped to reduce its circumferential size.
When a collapsed prosthetic valve has reached the desired implant site in the patient (e.g., at or near the annulus of the patient's heart valve that is to be replaced by the prosthetic valve), the prosthetic valve can be deployed or released from the delivery apparatus and re-expanded to full operating size. For balloon-expandable valves, this generally involves releasing the entire valve, assuring its proper location, and then expanding a balloon positioned within the valve stent. For self-expanding valves, on the other hand, the stent automatically expands as the sheath covering the valve is withdrawn.
In some embodiments, a prosthetic heart valve having an inflow end and an outflow end includes a stent having a collapsed condition, an expanded condition, and a plurality of cells arranged in circumferential rows. The stent has an anterior side configured and arranged to be disposed adjacent an anterior native valve leaflet and a posterior side configured and arranged to be disposed adjacent a posterior native valve leaflet. A valve assembly having a plurality of leaflets is disposed within the stent and a flange is disposed about the stent, the flange having a flared portion adjacent the inflow end of the prosthetic heart valve and a body portion extending from the flared portion to the outflow end. The flange extends between a first set of attachment points adjacent the inflow end and a second set of attachment points adjacent the outflow end.
In some embodiments, a prosthetic heart valve having an inflow end and an outflow end includes a stent having a collapsed condition, an expanded condition, and a plurality of cells arranged in circumferential rows. The stent has an anterior side configured and arranged to be disposed adjacent an anterior native valve leaflet and a posterior side configured and arranged to be disposed adjacent a posterior native valve leaflet. A valve assembly having a plurality of leaflets is disposed within the stent and a flange is disposed about the stent, the flange being asymmetric about a longitudinal axis such that a posterior side of the flange has a different shape than an anterior side of the flange.
Various embodiments of the present disclosure are described herein with reference to the drawings, wherein:
Blood flows through the mitral valve from the left atrium to the left ventricle. As used herein, the term “inflow end,” when used in connection with a prosthetic mitral heart valve, refers to the end of the heart valve closest to the left atrium when the heart valve is implanted in a patient, whereas the term “outflow end,” when used in connection with a prosthetic mitral heart valve, refers to the end of the heart valve closest to the left ventricle when the heart valve is implanted in a patient. Also, as used herein, the terms “substantially,” “generally,” and “about” are intended to mean that slight deviations from absolute are included within the scope of the term so modified. Generally, materials described as being suitable for components in one embodiment of the disclosure may also be suitable for similar or identical components described in other embodiments.
A dashed arrow, labeled “TA”, indicates a transapical approach for implanting a prosthetic heart valve, in this case to replace the mitral valve. In transapical delivery, a small incision is made between the ribs and into the apex of left ventricle 124 to deliver the prosthetic heart valve to the target site. A second dashed arrow, labeled “TS”, indicates a transseptal approach for implanting a prosthetic heart valve in which the valve is passed through the septum between right atrium 112 and left atrium 122. Other approaches for implanting a prosthetic heart valve are also possible.
Prosthetic heart valve 300 may include stent 350, which may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape-memory alloys including nitinol. Stent 350 may include a plurality of struts 352 that form cells 354 connected to one another in one or more annular rows around the stent. Cells 354 may all be of substantially the same size around the perimeter and along the length of stent 350. Alternatively, cells 354 near inflow end 310 may be larger than the cells near outflow end 312. Stent 350 may be expandable to provide a radial force to assist with positioning and stabilizing prosthetic heart valve 300 in the native valve annulus.
Prosthetic heart valve 300 may also include a substantially cylindrical valve assembly 360 including a plurality of leaflets 362 (
When prosthetic heart valve 300 is implanted in a patient, for example at the annulus of native mitral valve 130, it is biased towards an expanded condition, providing radial force to anchor the valve in place. However, if the radial force is too high, damage may occur to heart tissue. If, instead, the radial force is too low, the heart valve may move from its implanted position, for example, into either left ventricle 124 or left atrium 122, requiring emergency surgery to remove the displaced valve. The potential for such movement may be heightened in mitral valve applications, particularly if a low profile valve is used.
Another potential issue with prosthetic heart valves is inadequate sealing between the prosthetic valve and the native tissue. For example, if prosthetic heart valve 300 is implanted at the annulus of mitral valve 130 in a patient, improper or inadequate sealing may result in blood flowing from left ventricle 124 into left atrium 122, even if leaflets 362 of valve assembly 360 are working properly. This may occur, for example, if blood flows in a retrograde fashion between the outer perimeter of prosthetic heart valve 300 and the native tissue at the site of implantation. This phenomenon is known as perivalvular (or paravalvular) leak (“PV leak”).
In addition to anchoring and perivalvular leakage, there are other considerations when forming a prosthetic heart valve for mitral applications. For example, the replacement valve may need to accommodate irregular or large mitral valve annuli without damaging nearby native structures or affecting electrical signals. Additionally, the replacement valve may address the location and position of the left ventricular outflow tract and try to limit obstruction of it. The replacement valve should also be simple to use and the ability of the valve to anchor within the native annulus should be easy and repeatable.
Other considerations may include the anchoring or securement of the posterior leaflet. Because of the relatively small size and location of the posterior leaflet in some patients, it may be difficult to visualize and capture the leaflet with an anchor. It would also be beneficial to reduce the risk of migration of the valve. Additionally, it would be beneficial to secure the native leaflets so that they do not obstruct blood flow, for example, into the left ventricular outflow tract or the aorta.
Prosthetic heart valve 400 may also include a valve assembly having three leaflets 462 attached to a cylindrical cuff 464 similar to that shown and described with reference to
As with stent 350, stent 450 may be expandable to provide a radial force to assist with positioning and stabilizing prosthetic heart valve 400 in the native mitral valve annulus. However, prosthetic valve 400 includes additional securement features in the form of anchor arms 470 to help prevent prosthetic heart valve 400 from migrating into left atrium 122. Anchor arms 470 may be separately attachable such that they hook under native mitral valve leaflets 136, 138 or may be cut directly into the stent 450, for example, via laser cutting.
A single anchor arm 470 is shown in
Prosthetic heart valve 400 is shown at a possible intermediate stage of manufacture in
As noted above, wire 472 forming anchor arms 470 is preferably made from a shape-memory alloy. By using a shape-memory alloy, the shape of anchor arms 470 may be set, for example by heat setting, to take the illustrated shape in the absence of applied forces. However, forces may be applied to anchor arms 470 and to prosthetic heart valve 400 generally to reduce the radial size and/or bulk of the prosthetic heart valve when in the collapsed condition, which may facilitate intravascular (or other minimally invasive) delivery of the prosthetic heart valve via a delivery device (not shown). For example, as shown in
As described above, the stent 450 of prosthetic heart valve 400 may include two circumferential rows of annular cells 454, with each row containing nine such cells. Although the use of nine cells 454 per row is merely an example, the use of an odd number of cells 454 per row in prosthetic heart valves for replacing native mitral valve 130 may cause difficulty in creating symmetry in the positioning of anchor arms 470 on the prosthetic heart valve.
While prosthetic heart valve 400 may be used as shown and described above in connection with
Additionally, prosthetic heart valve 500 includes flange 580 to facilitate the anchoring of the heart valve within native mitral valve annulus 130 and the prevention of PV leak. Flange 580 may be formed of a material braided to create various shapes and/or geometries to engage tissue. As shown in
Flange 580 may include a body portion 582 terminating at an outflow end of the flange and a flared portion 584 terminating at an inflow end of the flange. Body portion 582 may be formed with a generally cylindrical or tubular geometry and may be configured to be circumferentially disposed around a portion of stent 550 and/or valve assembly 560. Flange 580 may be coupled to stent 550 (and optionally to the leaflets and/or cuff) by sutures, for example. Flange 580 may be alternatively or additionally connected to stent 550 via a coupler, ultrasonic welds, laser welding, glue, adhesives, or other suitable means. In one particular embodiment, the wires 586 of the flange 580 are collected in marker bands and welded in groups, for example in a quantity of 12, although alternative quantities are possible. A coupler tube, formed of stainless steel, nitinol, platinum/iridium, MP35N, titanium, or the like, with corrosion resistance and suitable weld strength properties, may then be welded, for example, via a laser, to a strut 552 of the stent. As shown in the profile of
When coupled to stent 550, body portion 582 of flange 580 is nearer outflow end 512 and flared portion 584 is nearer inflow end 510. In the expanded condition, flared portion 584 extends a greater distance radially outwardly from the longitudinal axis L of prosthetic heart valve 500 than body portion 582. In other words, as shown in
Flange 580 may be preset to take the illustrated shape in the absence of external forces. As with stent 450 and anchor arms 470 of
Prosthetic heart valve 500 may be delivered to the implant site in the collapsed condition and, when in the desired position relative to native mitral valve 130, transitioned to the expanded condition, for example by removing the surrounding sheath of the delivery device. During the transition from the collapsed condition to the expanded condition, anchor arms 570 revert to the preset shape, capturing native mitral valve leaflets 136, 138 between anchor arms 570 and corresponding portions of stent 550. Flange 580 also transitions from the collapsed condition to the expanded condition, assuming its preset shape. When implanted and in the expanded condition, flange 580 provides a large surface area to help anchor prosthetic valve 500 within the native valve annulus, and may be particularly effective at resisting movement of prosthetic heart valve 500 toward left ventricle 124. Specifically, flange 580 is sized to have an expanded diameter that is too large to pass through the native valve annulus. Because flange 580 is coupled to stent 550, prosthetic heart valve 500 is restricted from migrating into left ventricle 124 during normal operation of prosthetic heart valve 500. Thus, the combination of anchor arms 570 engaged with the mitral valve leaflets, and flange 580 engaged with the tissue on the atrial side of the mitral valve annulus, helps to securely anchor prosthetic heart valve 500 within the mitral valve annulus and limits its migration toward either the left atrium or the left ventricle.
In addition to providing anchoring capabilities, flange 580 may improve sealing between prosthetic heart valve 500 and the native valve annulus. For example, a covering layer 588, such as a polyester fabric or tissue, may be placed over portions 5A1,5A2 of flange 580 (
Prosthetic heart valve 600 may include stent 650, which generally extends between inflow end 610 and outflow end 612 and includes a plurality of struts forming rows of cells. CAFs (not shown) may be included near outflow end 612 for coupling the leaflets to the stent. Prosthetic heart valve 600 may also include a flange 680 similar to flange 580 described above, and formed of any of the materials described, such as braided nitinol wires.
In contrast to the previous embodiments, flange 680 has an asymmetric configuration about a central longitudinal axis L of prosthetic heart valve 600. Specifically, the flange forms different shapes on the anterior and posterior sides of the prosthetic heart valve. On the posterior side, flange 680 has a flared portion 684P and a body portion 682P that are similar to those of
Conversely, on the anterior side of the prosthetic heart valve, flange 680 has the same or similar flared portion 684A, but a different body portion 682A which leaves an exposed portion 685A of stent 650 that is much larger than exposed portion 685P. Specifically, body portion 682A is formed such that only about half of stent 650 is covered by flange 680 on the anterior side. In at least some examples, exposed portion 685A of stent 650 is between about 10% and about 80% of the total length of stent 650 in the fully expanded condition, or between about 30% and about 60% of the total length of stent 650. Additionally, the coverage of flange 680 may be determined by the location of its points of attachment to stent 650. For example, in the example shown in
The relatively large exposed portion 685A at the anterior side of the stent permits uninterrupted blood flow and avoids obstruction of the left ventricular outflow tract. To further assist in limiting obstruction of the left ventricular outflow tract, one or more anchor arms 670 may be disposed adjacent exposed portion 685A to retain the native valve leaflet in place during operation of the valve and further prevent the native valve leaflet from moving toward the left ventricular outflow tract. Conversely, on the posterior side, a plurality of stabilizing wires 672 may be used instead of an anchoring arm. In fact, stabilizing wires 672 may be disposed circumferentially around flange 680 at all locations. The stabilizing wires 672, which may be in the form of a hook or a barb, push against or pierce native tissue during radial expansion to further stabilize the prosthetic heart valve. Because the posterior native leaflet and the anterior native leaflet have different sizes and geometries, the use of a combination of stabilizing wires and anchor arms may yield better anchoring than a symmetric configuration. For example, the shorter native posterior leaflet may be more easily grasped with wires 672 than with an anchor arm.
A variation of prosthetic heart valve 600 is shown in
Another variation of prosthetic heart valve 600 is shown in
In yet another example, prosthetic heart valve 700C having stent 750C and asymmetric flange 780C is shown in
It will be understood that the shape of the flange may be modified as desired. For example,
According to the disclosure, a prosthetic heart valve has an inflow end and an outflow end, and may include a stent having a collapsed condition, an expanded condition, and a plurality of cells arranged in circumferential rows, the stent has an anterior side configured and arranged to be disposed adjacent an anterior native valve leaflet, and a posterior side configured and arranged to be disposed adjacent a posterior native valve leaflet, a valve assembly disposed within the stent and with a plurality of leaflets, and a flange disposed about the stent, the flange has a flared portion adjacent the inflow end of the prosthetic heart valve and a body portion that extends from the flared portion to the outflow end, the flange extends between a first set of attachment points adjacent the inflow end, and a second set of attachment points adjacent the outflow end; and/or
the flange is formed of a braided mesh, and the body portion extends a first distance toward the outflow end on one side of the prosthetic heart valve, and extends a second distance toward the outflow end on another side of the prosthetic heart valve, the second distance being less than the first distance; and/or
the body portion extends over the stent to define a first exposed portion of the stent on the anterior side of the stent, and a second exposed portion of the stent on the posterior side of the stent, the first exposed portion being larger than the second exposed portion; and/or
the body portion extends over the stent to define a first exposed portion of the stent on the anterior side of the stent, the first exposed portion being configured and arranged to allow unimpeded blood flow through the left ventricular outflow tract; and/or
the body portion covers about half of the stent on an anterior side of the stent; and/or
the flared portion is symmetric about a longitudinal axis of the stent; and/or
the prosthetic heart valve further includes a cover layer disposed over at least a portion of the flange; and/or
the prosthetic heart valve further includes at least one anchor arm disposed adjacent the anterior side of the stent; and/or
the prosthetic heart valve further includes a plurality of stabilizing wires disposed adjacent a posterior side of the stent; and/or
the flared portion of the flange has a first diameter in an expanded condition of the flange and the body portion of the flange has a second diameter in the expanded condition of the flange, the second diameter being smaller than the first diameter; and/or
both the flared portion and the body portion of the flange have circular lateral cross-sections in an expanded condition of the flange;
the flared portion has a circular lateral cross-section in an expanded condition of the flange, and the body portion of the flange has an oval lateral cross-section in an expanded condition of the flange.
According to the disclosure, a prosthetic heart valve may also have an inflow end and an outflow end, a stent having a collapsed condition, an expanded condition, and a plurality of cells arranged in circumferential rows, the stent has an anterior side configured and arranged to be disposed adjacent an anterior native valve leaflet, and a posterior side configured and arranged to be disposed adjacent a posterior native valve leaflet, a valve assembly disposed within the stent and with a plurality of leaflets, and a flange disposed about the stent, the flange being asymmetric about a longitudinal axis such that a posterior side of the flange has a different shape than an anterior side of the flange; and/or
the flange is formed of a braided mesh and has a flared portion adjacent the inflow end of the prosthetic heart valve and a body portion extending from the flared portion to the outflow end; and/or
the flared portion has a same shape on the anterior side of the flange and on the posterior side of the flange, and the body portion has a different shape on the anterior side of the flange than on the posterior side of the flange; and/or
the body portion extends a first distance toward the outflow end on one side of the prosthetic heart valve, and extends a second distance toward the outflow end on another side of the prosthetic heart valve, the second distance being less than the first distance; and/or
the body portion extends over the stent to define a first exposed portion of the stent on the anterior side of the stent, and a second exposed portion of the stent on the posterior side of the stent, the first exposed portion being larger than the second exposed portion; and/or
the body portion extends over the stent to define a first exposed portion of the stent on the anterior side of the stent, the first exposed portion being configured and arranged to allow unimpeded blood flow through the left ventricular outflow tract; and/or
the prosthetic heart valve further includes at least one anchor arm disposed adjacent the anterior side of the stent, and a plurality of stabilizing wires disposed adjacent a posterior side of the stent; and/or
the flange is formed of at least two portions of material that overlap one another.
Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the appended claims. For example, any of the anchor arms described above may be integrally formed with the stent and laser cut from the stent body. In addition, features of embodiments described herein may be combined with features of other embodiments described herein without departing from the scope of the invention.
This application is a continuation of U.S. patent application Ser. No. 15/796,184, filed Oct. 27, 2017, now U.S. Pat. No. 10,441,421 which claims the benefit of the filing date of U.S. Provisional Application No. 62/457,374, filed Feb. 10, 2017, and U.S. Provisional Application No. 62/414,125, filed Oct. 28, 2016, the disclosures of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3657744 | Ersek | Apr 1972 | A |
4275469 | Gabbay | Jun 1981 | A |
4491986 | Gabbay | Jan 1985 | A |
4759758 | Gabbay | Jul 1988 | A |
4878906 | Lindemann et al. | Nov 1989 | A |
4922905 | Strecker | May 1990 | A |
4994077 | Dobben | Feb 1991 | A |
5411552 | Andersen et al. | May 1995 | A |
5415664 | Pinchuk | May 1995 | A |
5480423 | Ravenscroft et al. | Jan 1996 | A |
5843167 | Dwyer et al. | Dec 1998 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5935163 | Gabbay | Aug 1999 | A |
5961549 | Nguyen et al. | Oct 1999 | A |
6045576 | Starr et al. | Apr 2000 | A |
6077297 | Robinson et al. | Jun 2000 | A |
6083257 | Taylor et al. | Jul 2000 | A |
6090140 | Gabbay | Jul 2000 | A |
6214036 | Letendre et al. | Apr 2001 | B1 |
6264691 | Gabbay | Jul 2001 | B1 |
6267783 | Letendre et al. | Jul 2001 | B1 |
6368348 | Gabbay | Apr 2002 | B1 |
6419695 | Gabbay | Jul 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6468660 | Ogle et al. | Oct 2002 | B2 |
6488702 | Besselink | Dec 2002 | B1 |
6517576 | Gabbay | Feb 2003 | B2 |
6533810 | Hankh et al. | Mar 2003 | B2 |
6582464 | Gabbay | Jun 2003 | B2 |
6610088 | Gabbay | Aug 2003 | B1 |
6623518 | Thompson et al. | Sep 2003 | B2 |
6652578 | Bailey et al. | Nov 2003 | B2 |
6685625 | Gabbay | Feb 2004 | B2 |
6716244 | Klaco | Apr 2004 | B2 |
6719789 | Cox | Apr 2004 | B2 |
6730118 | Spenser et al. | May 2004 | B2 |
6783556 | Gabbay | Aug 2004 | B1 |
6790230 | Beyersdorf et al. | Sep 2004 | B2 |
6814746 | Thompson et al. | Nov 2004 | B2 |
6830584 | Seguin | Dec 2004 | B1 |
6869444 | Gabbay | Mar 2005 | B2 |
6893460 | Spenser et al. | May 2005 | B2 |
6908481 | Cribier | Jun 2005 | B2 |
6951573 | Dilling | Oct 2005 | B1 |
7018406 | Seguin et al. | Mar 2006 | B2 |
7025780 | Gabbay | Apr 2006 | B2 |
7137184 | Schreck | Nov 2006 | B2 |
7160322 | Gabbay | Jan 2007 | B2 |
7195641 | Palmaz et al. | Mar 2007 | B2 |
7247167 | Gabbay | Jul 2007 | B2 |
7267686 | DiMatteo et al. | Sep 2007 | B2 |
7276078 | Spenser et al. | Oct 2007 | B2 |
7311730 | Gabbay | Dec 2007 | B2 |
7320704 | Lashinski et al. | Jan 2008 | B2 |
7329278 | Seguin et al. | Feb 2008 | B2 |
7374573 | Gabbay | May 2008 | B2 |
7381218 | Schreck | Jun 2008 | B2 |
7381219 | Salahieh et al. | Jun 2008 | B2 |
7452371 | Pavcnik et al. | Nov 2008 | B2 |
7510572 | Gabbay | Mar 2009 | B2 |
7510575 | Spenser et al. | Mar 2009 | B2 |
7524331 | Birdsall | Apr 2009 | B2 |
7534261 | Friedman | May 2009 | B2 |
RE40816 | Taylor et al. | Jun 2009 | E |
7585321 | Cribier | Sep 2009 | B2 |
7628805 | Spenser et al. | Dec 2009 | B2 |
7682390 | Seguin | Mar 2010 | B2 |
7708775 | Rowe et al. | May 2010 | B2 |
7731742 | Schlick et al. | Jun 2010 | B2 |
7748389 | Salahieh et al. | Jul 2010 | B2 |
7780725 | Haug et al. | Aug 2010 | B2 |
7799069 | Bailey et al. | Sep 2010 | B2 |
7803185 | Gabbay | Sep 2010 | B2 |
7824442 | Salahieh et al. | Nov 2010 | B2 |
7837727 | Goetz et al. | Nov 2010 | B2 |
7846203 | Cribier | Dec 2010 | B2 |
7846204 | Letac et al. | Dec 2010 | B2 |
7857845 | Stacchino et al. | Dec 2010 | B2 |
7892281 | Seguin et al. | Feb 2011 | B2 |
7914569 | Nguyen et al. | Mar 2011 | B2 |
7959666 | Salahieh et al. | Jun 2011 | B2 |
7959672 | Salahieh et al. | Jun 2011 | B2 |
7972378 | Tabor et al. | Jul 2011 | B2 |
7988724 | Salahieh et al. | Aug 2011 | B2 |
7993394 | Hariton et al. | Aug 2011 | B2 |
8016877 | Seguin et al. | Sep 2011 | B2 |
D648854 | Braido | Nov 2011 | S |
8048153 | Salahieh et al. | Nov 2011 | B2 |
8052741 | Bruszewski et al. | Nov 2011 | B2 |
8052749 | Salahieh et al. | Nov 2011 | B2 |
8052750 | Tuval et al. | Nov 2011 | B2 |
8062355 | Figulla et al. | Nov 2011 | B2 |
8075611 | Millwee et al. | Dec 2011 | B2 |
D652926 | Braido | Jan 2012 | S |
D652927 | Braido et al. | Jan 2012 | S |
D653341 | Braido et al. | Jan 2012 | S |
D653342 | Braido et al. | Jan 2012 | S |
D653343 | Ness et al. | Jan 2012 | S |
D654169 | Braido | Feb 2012 | S |
D654170 | Braido et al. | Feb 2012 | S |
8137398 | Tuval et al. | Mar 2012 | B2 |
8142497 | Friedman | Mar 2012 | B2 |
D660432 | Braido | May 2012 | S |
D660433 | Braido et al. | May 2012 | S |
D660967 | Braido et al. | May 2012 | S |
8182528 | Salahieh et al. | May 2012 | B2 |
8221493 | Boyle et al. | Jul 2012 | B2 |
8230717 | Matonick | Jul 2012 | B2 |
8231670 | Salahieh et al. | Jul 2012 | B2 |
8252051 | Chau et al. | Aug 2012 | B2 |
8308798 | Pintor et al. | Nov 2012 | B2 |
8313525 | Tuval et al. | Nov 2012 | B2 |
8323335 | Rowe et al. | Dec 2012 | B2 |
8323336 | Hill et al. | Dec 2012 | B2 |
8343213 | Salahieh et al. | Jan 2013 | B2 |
8348995 | Tuval et al. | Jan 2013 | B2 |
8348996 | Tuval et al. | Jan 2013 | B2 |
8348998 | Pintor et al. | Jan 2013 | B2 |
8366769 | Huynh et al. | Feb 2013 | B2 |
8403983 | Quadri et al. | Mar 2013 | B2 |
8408214 | Spenser | Apr 2013 | B2 |
8414643 | Tuval et al. | Apr 2013 | B2 |
8425593 | Braido et al. | Apr 2013 | B2 |
8449599 | Chau et al. | May 2013 | B2 |
8449604 | Moaddeb et al. | May 2013 | B2 |
D684692 | Braido | Jun 2013 | S |
8454686 | Alkhatib | Jun 2013 | B2 |
8500798 | Rowe et al. | Aug 2013 | B2 |
8568474 | Yeung et al. | Oct 2013 | B2 |
8579962 | Salahieh et al. | Nov 2013 | B2 |
8579966 | Seguin et al. | Nov 2013 | B2 |
8585755 | Chau et al. | Nov 2013 | B2 |
8591575 | Cribier | Nov 2013 | B2 |
8597349 | Alkhatib | Dec 2013 | B2 |
8603159 | Seguin et al. | Dec 2013 | B2 |
8603160 | Salahieh et al. | Dec 2013 | B2 |
8613765 | Bonhoeffer et al. | Dec 2013 | B2 |
8623074 | Ryan | Jan 2014 | B2 |
8652204 | Quill et al. | Feb 2014 | B2 |
8663322 | Keranen | Mar 2014 | B2 |
8668733 | Haug et al. | Mar 2014 | B2 |
8685080 | White | Apr 2014 | B2 |
8728154 | Alkhatib | May 2014 | B2 |
8747459 | Nguyen et al. | Jun 2014 | B2 |
8764820 | Dehdashtian et al. | Jul 2014 | B2 |
8795357 | Yohanan et al. | Aug 2014 | B2 |
8801776 | House et al. | Aug 2014 | B2 |
8808356 | Braido et al. | Aug 2014 | B2 |
8828078 | Salahieh et al. | Sep 2014 | B2 |
8834563 | Righini | Sep 2014 | B2 |
8840661 | Manasse | Sep 2014 | B2 |
8840663 | Salahieh et al. | Sep 2014 | B2 |
8876894 | Tuval et al. | Nov 2014 | B2 |
8876895 | Tuval et al. | Nov 2014 | B2 |
8940040 | Shahriari | Jan 2015 | B2 |
8945209 | Bonyuet et al. | Feb 2015 | B2 |
8961595 | Alkhatib | Feb 2015 | B2 |
8974523 | Thill et al. | Mar 2015 | B2 |
8974524 | Yeung et al. | Mar 2015 | B2 |
20020036220 | Gabbay | Mar 2002 | A1 |
20030023303 | Palmaz et al. | Jan 2003 | A1 |
20030050694 | Yang et al. | Mar 2003 | A1 |
20030130726 | Thorpe et al. | Jul 2003 | A1 |
20040049262 | Obermiller et al. | Mar 2004 | A1 |
20040093075 | Kuehne | May 2004 | A1 |
20040111111 | Lin | Jun 2004 | A1 |
20040210304 | Seguin et al. | Oct 2004 | A1 |
20040220593 | Greenhalgh | Nov 2004 | A1 |
20040260389 | Case et al. | Dec 2004 | A1 |
20050096726 | Sequin et al. | May 2005 | A1 |
20050137682 | Justino | Jun 2005 | A1 |
20050137695 | Salahieh et al. | Jun 2005 | A1 |
20050137697 | Salahieh et al. | Jun 2005 | A1 |
20050203605 | Dolan | Sep 2005 | A1 |
20050240200 | Bergheim | Oct 2005 | A1 |
20050256566 | Gabbay | Nov 2005 | A1 |
20060008497 | Gabbay | Jan 2006 | A1 |
20060074484 | Huber | Apr 2006 | A1 |
20060122692 | Gilad et al. | Jun 2006 | A1 |
20060149360 | Schwammenthal et al. | Jul 2006 | A1 |
20060161249 | Realyvasquez et al. | Jul 2006 | A1 |
20060173532 | Flagle et al. | Aug 2006 | A1 |
20060178740 | Stacchino et al. | Aug 2006 | A1 |
20060195180 | Kheradvar et al. | Aug 2006 | A1 |
20060206202 | Bonhoeffer et al. | Sep 2006 | A1 |
20060241744 | Beith | Oct 2006 | A1 |
20060241745 | Solem | Oct 2006 | A1 |
20060259120 | Vongphakdy et al. | Nov 2006 | A1 |
20060259137 | Artof et al. | Nov 2006 | A1 |
20060265056 | Nguyen et al. | Nov 2006 | A1 |
20060276813 | Greenberg | Dec 2006 | A1 |
20060276874 | Wilson et al. | Dec 2006 | A1 |
20070010876 | Salahieh et al. | Jan 2007 | A1 |
20070027534 | Bergheim et al. | Feb 2007 | A1 |
20070043435 | Seguin et al. | Feb 2007 | A1 |
20070055358 | Krolik et al. | Mar 2007 | A1 |
20070067029 | Gabbay | Mar 2007 | A1 |
20070093890 | Eliasen et al. | Apr 2007 | A1 |
20070100435 | Case et al. | May 2007 | A1 |
20070118210 | Pinchuk | May 2007 | A1 |
20070213813 | Von Segesser et al. | Sep 2007 | A1 |
20070233228 | Eberhardt et al. | Oct 2007 | A1 |
20070244545 | Birdsall et al. | Oct 2007 | A1 |
20070244552 | Salahieh et al. | Oct 2007 | A1 |
20070288087 | Fearnot et al. | Dec 2007 | A1 |
20080021552 | Gabbay | Jan 2008 | A1 |
20080039934 | Styrc | Feb 2008 | A1 |
20080071369 | Tuval et al. | Mar 2008 | A1 |
20080082164 | Friedman | Apr 2008 | A1 |
20080097595 | Gabbay | Apr 2008 | A1 |
20080114452 | Gabbay | May 2008 | A1 |
20080125853 | Bailey et al. | May 2008 | A1 |
20080140189 | Nguyen et al. | Jun 2008 | A1 |
20080147183 | Styrc | Jun 2008 | A1 |
20080154355 | Benichou et al. | Jun 2008 | A1 |
20080154356 | Obermiller et al. | Jun 2008 | A1 |
20080183273 | Mesana et al. | Jul 2008 | A1 |
20080243245 | Thambar et al. | Oct 2008 | A1 |
20080255662 | Stacchino et al. | Oct 2008 | A1 |
20080262602 | Wilk et al. | Oct 2008 | A1 |
20080269879 | Sathe et al. | Oct 2008 | A1 |
20080275549 | Rowe | Nov 2008 | A1 |
20080288055 | Paul, Jr. | Nov 2008 | A1 |
20090099653 | Suri et al. | Apr 2009 | A1 |
20090112309 | Jaramillo et al. | Apr 2009 | A1 |
20090138071 | Cheng et al. | May 2009 | A1 |
20090138079 | Tuval et al. | May 2009 | A1 |
20090276027 | Glynn | Nov 2009 | A1 |
20090276040 | Rowe et al. | Nov 2009 | A1 |
20100004740 | Seguin et al. | Jan 2010 | A1 |
20100030244 | Woolfson et al. | Feb 2010 | A1 |
20100036484 | Hariton et al. | Feb 2010 | A1 |
20100049306 | House et al. | Feb 2010 | A1 |
20100087907 | Lattouf | Apr 2010 | A1 |
20100131055 | Case et al. | May 2010 | A1 |
20100168778 | Braido | Jul 2010 | A1 |
20100168839 | Braido et al. | Jul 2010 | A1 |
20100168844 | Toomes et al. | Jul 2010 | A1 |
20100185277 | Braido et al. | Jul 2010 | A1 |
20100191326 | Alkhatib | Jul 2010 | A1 |
20100204781 | Alkhatib | Aug 2010 | A1 |
20100204785 | Alkhatib | Aug 2010 | A1 |
20100217382 | Chau et al. | Aug 2010 | A1 |
20100234940 | Dolan | Sep 2010 | A1 |
20100249894 | Oba et al. | Sep 2010 | A1 |
20100249911 | Alkhatib | Sep 2010 | A1 |
20100249923 | Alkhatib et al. | Sep 2010 | A1 |
20100286768 | Alkhatib | Nov 2010 | A1 |
20100298931 | Quadri et al. | Nov 2010 | A1 |
20110029072 | Gabbay | Feb 2011 | A1 |
20110054466 | Rothstein et al. | Mar 2011 | A1 |
20110098800 | Braido et al. | Apr 2011 | A1 |
20110098802 | Braido et al. | Apr 2011 | A1 |
20110137397 | Chau et al. | Jun 2011 | A1 |
20110172765 | Nguyen et al. | Jul 2011 | A1 |
20110208283 | Rust | Aug 2011 | A1 |
20110264206 | Tabor | Oct 2011 | A1 |
20120035722 | Tuval | Feb 2012 | A1 |
20120078347 | Braido et al. | Mar 2012 | A1 |
20120078353 | Quadri et al. | Mar 2012 | A1 |
20120101572 | Kovalsky et al. | Apr 2012 | A1 |
20120123529 | Levi et al. | May 2012 | A1 |
20120303116 | Gorman, III et al. | Nov 2012 | A1 |
20130274873 | Delaloye et al. | Oct 2013 | A1 |
20130310928 | Morriss | Nov 2013 | A1 |
20140046434 | Rolando et al. | Feb 2014 | A1 |
20140121763 | Duffy et al. | May 2014 | A1 |
20140155997 | Braido | Jun 2014 | A1 |
20140214159 | Vidlund et al. | Jul 2014 | A1 |
20140228946 | Chau et al. | Aug 2014 | A1 |
20140236292 | Braido | Aug 2014 | A1 |
20140257466 | Board | Sep 2014 | A1 |
20140277411 | Bortlein et al. | Sep 2014 | A1 |
20140303719 | Cox et al. | Oct 2014 | A1 |
20140324164 | Gross et al. | Oct 2014 | A1 |
20140343671 | Yohanan et al. | Nov 2014 | A1 |
20140350668 | Delaloye et al. | Nov 2014 | A1 |
20140350669 | Gillespie et al. | Nov 2014 | A1 |
20140371844 | Dale et al. | Dec 2014 | A1 |
20150238315 | Rabito | Aug 2015 | A1 |
20150335429 | Morriss et al. | Nov 2015 | A1 |
20160030170 | Alkhatib et al. | Feb 2016 | A1 |
20160278923 | Krans et al. | Sep 2016 | A1 |
20160331529 | Marchand et al. | Nov 2016 | A1 |
20180153687 | Hariton | Jun 2018 | A1 |
Number | Date | Country |
---|---|---|
19857887 | Jul 2000 | DE |
10121210 | Nov 2005 | DE |
102005003632 | Aug 2006 | DE |
202008009610 | Dec 2008 | DE |
0850607 | Jul 1998 | EP |
1000590 | May 2000 | EP |
1584306 | Oct 2005 | EP |
1598031 | Nov 2005 | EP |
1360942 | Dec 2005 | EP |
1926455 | Jun 2008 | EP |
2537487 | Dec 2012 | EP |
2896387 | Jul 2015 | EP |
2850008 | Jul 2004 | FR |
2847800 | Oct 2005 | FR |
9117720 | Nov 1991 | WO |
9716133 | May 1997 | WO |
9832412 | Jul 1998 | WO |
9913801 | Mar 1999 | WO |
01028459 | Apr 2001 | WO |
2001049213 | Jul 2001 | WO |
01056500 | Aug 2001 | WO |
2001054625 | Aug 2001 | WO |
2001076510 | Oct 2001 | WO |
2002036048 | May 2002 | WO |
0247575 | Jun 2002 | WO |
02067782 | Sep 2002 | WO |
2003047468 | Jun 2003 | WO |
2005070343 | Aug 2005 | WO |
06073626 | Jul 2006 | WO |
07071436 | Jun 2007 | WO |
2008070797 | Jun 2008 | WO |
10008548 | Jan 2010 | WO |
2010008549 | Jan 2010 | WO |
2010096176 | Aug 2010 | WO |
2010098857 | Sep 2010 | WO |
2012178115 | Dec 2012 | WO |
Entry |
---|
International Search report for PCT/US2017/058649 dated Apr. 4, 2018, 6 pages. |
Ruiz, Carlos, Overview of PRE-CE Mark Transcatheter Aortic Valve Technologies, Euro PCR—dated May 25, 2010. |
Quaden, et al. “Percutaneous Aortic Valve Replacement: Resection Before Implantation”, European Journal of Cardio-Thoracic Surgery, vol. 27, No. 5, May 2005, pp. 836-840. |
Braido et al., Design U.S. Appl. No. 29/375,243, filed Sep. 20, 2010. |
Knudsen, et al., “Catheter-Implanted Prosthetic Heart Valves: Transluminal Catheter Implantation of a New Expandable Artificial Heart Valve in the Descending Thoracic Aorta in Isolated Vessels and Closed Chest Pigs”, The International Journal of Artificial Organs, May 1993, vol. 16, No. 5, pp. 253-262. |
Moazami, et al., “Transluminal Aortic Valve Placement. A Feasibility Study with a Newly Designed Collapsible Aortic Valve”, ASAIO Journal (American Society for Artificial Internal Organs: 1992), vol. 42, No. 5, 1996, pp. M381-M385. |
Andersen, H.R., “Transluminal Catheter Implanted Prosthetic Heart Valves”, International Journal of Angiology, vol. 7, No. 2, Mar. 1998, pp. 102-106. |
Andersen, et al., “Transluminal Implantation of Artificial Heart Valves. Description of a New Expandable Aortic Valve and Initial Results with Implantation by Catheter Technique in Closed Chest Pigs”, European Heart Journal, vol. 13, No. 5, May 1992, pp. 704-708. |
Is It Reasonable to Treat All Calcified Stenotic Aortic Valves With a Valved Stent?, 579-584, Zegdi, Rachid, MD, PhD et al., J. of the American College of Cardiology, vol. 51, No. 5, Feb. 5, 2008. |
“Direct-Access Valve Replacement”, Christoph H. Huber, et al., Journal of the American College of Cardiology, vol. 46, No. 2, (Jul. 19, 2005). |
“Percutaneous Aortic Valve Implantation Retrograde From the Femoral Artery”, John G. Webb et al., Circulation, 2006; 113:842-850 (Feb. 6, 2006). |
“Minimally invasive cardiac surgery”, M. J. Mack, Surgical Endoscopy, 2006, 20:S488-S492, DOI: 10.1007/s00464-006-0110-8 (presented Apr. 24, 2006). |
“Transapical Transcatheter Aortic Valve Implantation in Humans”, Samuel V. Lichtenstein et al.. Circulation. 2006; 114: 591-596 (Jul. 31, 2006). |
Lichtenstein, S.V., “Closed Heart Surgery: Back to the Future”, The Journal of Thoracic and Cardiovascular Surgery, vol. 131, No. 5, May 2006, pp. 941-943. |
Walther, et al., “Transapical Approach for Sutureless Stent-Fixed Aortic Valve Implantation: Experimental Results”, European Journal of Cardio-Thoracic Surgery, vol. 29, No. 5, May 2006, pp. 703-708. |
“Transapical aortic valve implantation: an animal feasibility study”; Todd M. Dewey et al., The annals of thoracic surgery 2006; 82: 110-6 (Feb. 13, 2006). |
Hijazi et al., “Transcatheter Valve Repair”, CRC Press, Jan. 2006, pp. 165-186. |
Rohde, et al., “Resection of Calcified Aortic Heart Leaflets In Vitro by Q-Switched 2 μm Microsecond Laser Radiation”, Journal of Cardiac Surgery, vol. 30, No. 2, Feb. 2015, pp. 157-162. |
Munoz, et al., “Guidance of Treatment of Perivalvular Prosthetic Leaks”, Current Cardiology Reports, vol. 16, No. 1, Nov. 2013, 6 pages. |
Gossl and Rihal, “Percutaneous Treatment of Aortic and Mitral Valve Paravalvular Regurgitation”, Current Cardiology Reports, vol. 15, No. 8, Aug. 2013, 8 pages. |
Swiatkiewicz, et al., “Percutaneous Closure of Mitral Perivalvular Leak”, Kardiologia Polska (Polish Heart Journal), vol. 67, No. 7, 2009, pp. 762-764. |
De Cicco, et al., “Aortic Valve Periprosthetic Leakage: Anatomic Observations and Surgical Results”, The Annals of Thoracic Surgery, vol. 79, No. 5, May 2005, pp. 1480-1485. |
Heart Advisor, “Heart Repairs Without Surgery. Minimally Invasive Procedures Aim to Correct Valve Leakage”, Sep. 2004, PubMed ID 15586429, 2 pages. |
Hourihan, et al., “Transcatheter Umbrella Closure of Valvular and Paravalvular Leaks”, Journal of the American College of Cardiology, vol. 20, No. 6, Nov. 1992, pp. 1371-1377. |
Buellesfeld and Meier, “Treatment of Paravalvular Leaks Through Interventional Techniques”, Multimedia Manual of Cardiothoracic Surgery, Department of Cardiology, Ben University Hospital, Jan. 2011, 8 pages. |
Number | Date | Country | |
---|---|---|---|
20190388225 A1 | Dec 2019 | US |
Number | Date | Country | |
---|---|---|---|
62457374 | Feb 2017 | US | |
62414125 | Oct 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15796184 | Oct 2017 | US |
Child | 16564691 | US |